Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Francesco Angotzi, Erika Borlenghi, Chiara Sartor, Maria Benedetta Giannini, Giovanni Marconi, Edoardo Tamellini, Mauro Turrini, Federica Loscocco, Ernesta Audisio, Vincenzo Federico, Calogero Vetro, Andrea Visentin, Carmela Gurrieri, Livio Trentin, Felicetto Ferrara, Federica Lessi

Blood (2024) 144 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2024-209605

Published: 2024

Journal Articles

River-81: A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess Safety, PK, PD, Clinical Efficacy of RVU120 in Combination with Venetoclax in Patients with AML Failing Prior Venetoclax Plus Hypomethylating Agent Therapy

Blood (2024) 144 (Supplement 1): 5999.

https://doi.org/10.1182/blood-2024-200055

Published: 2024

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Blood (2021) 138 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2021-149459

Published: 2021

Journal Articles

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-138371

Published: 2020

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Sonia Ronconi, Michela Ceccolini, MD, Delia Cangini, Maria Benedetta Giannini, MD, Valeria Di Battista, Giorgia Simonetti, PhD, Andrea Ghelli Luserna Di Rorà, PhD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143143

Published: 2020

Journal Articles

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-143082

Published: 2020

Journal Articles

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-139981

Published: 2020

Journal Articles

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2018) 132 (Supplement 1): 4365.

https://doi.org/10.1182/blood-2018-99-117714

Published: 2018

Journal Articles

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2016) 128 (22): 3169.

https://doi.org/10.1182/blood.V128.22.3169.3169

Published: 2016

Journal Articles

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Blood (2015) 126 (23): 2871.

https://doi.org/10.1182/blood.V126.23.2871.2871

Published: 2015

Journal Articles

Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study

Carlo Finelli, MD, Cristina Clissa, MD, Matilde Y Follo, PhD, Marta Stanzani, MD PhD, Paolo Avanzini, Costanza Bosi, MD, Barbara Castagnari, MD, Anna Candoni, MD, Monica Crugnola, MD, Maria Benedetta Giannini, MD, Marco Gobbi, MD, Giovanna Leonardi, MD, Gian Matteo Rigolin, MD, Patrizia Tosi, MD, Giuseppe Visani, MD, Lucio Cocco, MD, Michele Cavo, MD, Domenico Russo, MD PhD

Blood (2014) 124 (21): 4648.

https://doi.org/10.1182/blood.V124.21.4648.4648

Published: 2014

Journal Articles

Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients

Gerardo Musuraca, MD, PhD, Serena De Matteis, Roberta Napolitano, Francesco Fabbri, Delia Cangini, MD, Michela Ceccolini, MD, Maria Benedetta Giannini, MD, Alessandro Lucchesi, MD, Sonia Ronconi, MD, Cristina Papayannidis, MD, Viviana Guadagnuolo, Giovanni Martinelli, MD, Paolo Savini, MD, Monica Tani, MD, Patrizia Tosi, MD, Dino Amadori, MD, Pier Paolo Fattori, MD, Wainer Zoli, Silvia Carloni

Blood (2013) 122 (21): 2289.

https://doi.org/10.1182/blood.V122.21.2289.2289

Published: 2013

Journal Articles

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Carlo Finelli, M.D., Cristina Clissa, M.D., Maria Teresa Voso, Maria Antonietta Aloe Spiriti, Massimo Breccia, Gianluca Gaidano, MD, PhD, Monica Crugnola, M.D., Maria Benedetta Giannini, M.D., Costanza Bosi, MD, Virginia Naso, MD, Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Giovanni Martinelli, Lucio Cocco, MD, Michele Baccarani, MD

Blood (2012) 120 (21): 4951.

https://doi.org/10.1182/blood.V120.21.4951.4951

Published: 2012

Journal Articles

Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.

Blood (2004) 104 (11): 4655.

https://doi.org/10.1182/blood.V104.11.4655.4655

Published: 2004

Journal Articles

Pretransplant Recipient Blood CD14+ preDC Levels Correlate with Increased Acute GVHD after Allogeneic PBSC Transplantation.

Mario Arpinati, MD, Panagiota Giannoullia, MD, Gabriella Chirumbolo, BS, Giulia Perrone, MD, Francesca Bonifazi, MD, Yogen Sanuthararajah, MD, Francesca Palandri, MD, Maria Benedetta Giannini, MD, Giuseppe Bandini, MD, Valeria Martelli, Sara Sanchini, BS, Michele Baccarani, MD, Damiano Rondelli, MD

Blood (2004) 104 (11): 1226.

https://doi.org/10.1182/blood.V104.11.1226.1226

Published: 2004

NARROW

Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

River-81: A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess Safety, PK, PD, Clinical Efficacy of RVU120 in Combination with Venetoclax in Patients with AML Failing Prior Venetoclax Plus Hypomethylating Agent Therapy

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study

Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.

Pretransplant Recipient Blood CD14+ preDC Levels Correlate with Increased Acute GVHD after Allogeneic PBSC Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only